Alpha-Helix Mimetics

Product Name Product Description Specification
SL#001 Mcl-1 Apoptosis
Release: 04/12/2016

Apoptosis is now considered an attractive mechanism underlying a new strategy in the treatment of cancer. Compounds interacting with the Bcl-2 family of proteins are critical regulators of the apoptotic process; therefore, they can be used as anticancer agents.

In library: Mcl-1 inhibitors
SL#002 Bcl-xL Apoptosis
Release: 04/12/2016

Apoptosis is now considered an attractive mechanism underlying a new strategy in the treatment of cancer. Compounds interacting with the Bcl-2 family of proteins are critical regulators of the apoptotic process; therefore, they can be used as anticancer agents.

In library: BH3 mimetic-1
SL#011 MDM2/p53
Release: 05/05/2016

MDM2/p53 is a protein-protein interaction (PPI) which regulates a variety of cellular pathways involved in the onset and development of cancer. MDM2 is a negative regulator of tumor suppression protein p53 thus making MDM2 an attractive target for anticancer therapeutics.

In library: PPI inhibitors-1 (MDM2/p53)
SL#025 BH3 mimetics
Release: 06/22/2016

Apoptosis is an attractive mechanism underlying a new strategy in the treatment of cancer. Compounds interacting with the Bcl-2 family of proteins are critical regulators of the apoptotic process; therefore, they can be used as anticancer agents [1].

In library: BH3 mimetic-2
SL#030 a-Helix mimetics
Release: 07/28/2016

α-Helix is the most common type of secondary structure in proteins [1]. It is well known that α-helix mimetics are biologically active in a number of therapeutically significant protein-protein interactions (PPIs). Notable examples include HDM2(HDM4)/p53 and the BCL-2 family of proteins.

In library: BH3 mimetic-1
SL#032 BH3 mimetics macrocycles
Release: 07/07/2016

Compounds interacting with the Bcl-2 family of proteins are critical regulators of the apoptotic process; they can, therefore, be used as anticancer agents [1].

In library: BH3 mimetic macrocycles